Accessibility Menu
BioArctic Ab (publ) logo

BioArctic Ab (publ)(OTC) BRCTF

Current Price$31.78
Market Cap$2.82BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2022)+21%
5 YearN/A
1 Year+65%
1 Month-9%
BioArctic Ab (publ) last closing stock price
MetricPriceDate
Last closeUSD 31.782026-07-22
BioArctic Ab (publ) stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 31.782026-07-15
1 month-9.2%USD 35.002026-06-22
3 month-3.22%USD 32.842026-04-23
Year to date-8.01%USD 34.552025-12-30
1 year+65.24%USD 19.232025-07-18
3 year+17.66%USD 27.012023-07-13
Since inception+20.61%USD 26.352022-11-29

BioArctic Ab (publ) Financials at a Glance

Market Cap

$2.82BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

SEK 1.15B

Net Income (TTM)

SEK 213.27M

EPS (TTM)

$0.26

P/E Ratio

121.62

Dividend

$0.21

Beta (Volatility)

0.00 (Low)

Price

$31.78

Volume

15

Open

$31.78

Previous Close

$31.78

Daily Range

$31.78 - $31.78

52-Week Range

$19.34 - $40.00

Estimated Earnings Date

Aug 26, 2026

BRCTF News

Medical personnel preparing an injection.

What Are the Clinical Development Phases?

Benjamin LockeAug 16, 2025

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About BioArctic Ab (publ)

BioArctic AB (publ) is a biotechnology company focused on developing innovative biological drugs for patients with central nervous system disorders. The company specializes in addressing high unmet medical needs in neurodegenerative diseases, including Alzheimer's and Parkinson's disease.

Products and Services
  • Development of monoclonal antibodies for CNS disorders
  • Clinical trials for lecanemab and exidavnemab
  • Research collaborations with Eisai and AbbVie
Growth Outlook
  • Phase 3 clinical trials for lecanemab show promising results
  • Strong pipeline with multiple candidates in various trial phases
  • Increasing market demand for CNS therapies presents growth opportunities
Financial Highlights
  • Recent quarterly revenue of 437.6 million SEK, a significant increase
  • Net income of 212.4 million SEK reflects strong operational performance
  • Cash and short-term investments total 2.03 billion SEK, ensuring liquidity
BioArctic AB (publ) is positioned in the healthcare sector, specifically within the pharmaceuticals industry, focusing on innovative treatments for neurodegenerative disorders. The company has made significant strides in its research and development efforts, particularly with its lead product candidates, which are currently undergoing various stages of clinical trials. The recent quarterly financial results indicate a robust revenue growth trajectory, underscoring the company's operational efficiency and market potential. With a strong cash position, BioArctic is well-equipped to continue its research initiatives and capitalize on emerging opportunities in the CNS therapeutic market.
AI Generated • Jun 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

141

CEO

Gunilla Christina Osswald, PhD

Website

www.bioarctic.se

Headquarters

Stockholm, AB 112 51, SE

BRCTF Financials

Key Financial Metrics (TTM)

Gross Margin

94.13%

Operating Margin

34.50%

Net Income Margin

18.59%

Return on Equity

10.44%

Return on Capital

68.02%

Return on Assets

7.96%

Earnings Yield

0.82%

Dividend Yield

0.68%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.82BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

88.72M

Volume

15

Avg. Volume

22.065

Financials (TTM)

Gross Profit

SEK 1.08B

Operating Income

SEK 395.70M

EBITDA

SEK 410.99M

Operating Cash Flow

SEK 1.25B

Capital Expenditure

-SEK 433.22M

Free Cash Flow

SEK 1.25B

Cash & ST Invst.

SEK 2.03B

Total Debt

SEK 40.74M

BioArctic Ab (publ) Performance Analysis

BioArctic Ab (publ) annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31SEK 22,558,637736.7%
20232023-12-31SEK 58,025,457157.2%
20242024-12-31SEK 24,341,109-58.1%
20252025-12-31SEK 203,834,737737.4%
BioArctic Ab (publ) sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-69.6%
Q32025-09-30-66.0%
Q42025-12-3137.7%
Q12026-03-31138.4%
BioArctic Ab (publ) annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31SEK -0.01-92.1%
20232023-12-31SEK 0.24N/A
20242024-12-31SEK -0.19N/A
20252025-12-31SEK 1.18N/A
BioArctic Ab (publ) sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-90.5%
Q32025-09-30-189.9%
Q42025-12-3189.8%
Q12026-03-312499.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

SEK 437.59M

-66.1%

Gross Profit

SEK 418.04M

-67.3%

Gross Margin

95.53%

N/A

Market Cap

$2.82BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.00M

N/A

Employees

141

N/A

Net Income

SEK 212.39M

-79.2%

EBITDA

SEK 203.98M

-81.1%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

SEK 2.03B

+158.0%

Total Debt

SEK 40.74M

-20.1%

Accounts Receivable

SEK 0.00

N/A

Inventory

SEK 0.00

N/A

Long Term Debt

SEK 25.04M

-33.5%

Short Term Debt

SEK 31.33M

+135.4%

Return on Assets

7.96%

N/A

Return on Invested Capital

17.34%

N/A

Free Cash Flow

-SEK 166.00M

-1508.1%

Operating Cash Flow

-SEK 166.00M

-1508.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MEOBFMesoblast Limited
$1.70+0.00%
GENSFGenus plc
$31.07+0.00%
HTSUFHisamitsu Pharmaceutical Co., Inc.
$29.00+0.00%
PHMMFPharma Mar, S.A.
$86.09+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
NVDANvidia
$206.84-0.01%

Questions About BRCTF

What is the current price of BioArctic Ab (publ)?

BioArctic Ab (publ) is trading at $31.78 per share.

What is the 52-week range for BioArctic Ab (publ)?

Over the past 52 weeks, BioArctic Ab (publ) has traded between $19.34 and $40.00.

How much debt does BioArctic Ab (publ) have?

As of the most recent reporting period, BioArctic Ab (publ) reported total debt of SEK 4.28M.

How much cash does BioArctic Ab (publ) have on hand?

BioArctic Ab (publ) reported SEK 126.46M in cash and cash equivalents in its most recent financial results.

What is BioArctic Ab (publ)’s dividend yield?

BioArctic Ab (publ) currently has a dividend yield of 0.68%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services